Intestinal inflammatory disorders are associated with neurophysiological and behavioral symptoms. Conversely, many disorders of the central nervous system (CNS) are accompanied by intestinal complications. These observations suggest that the physiologies of the intestine and nervous system are functionally linked. Indeed, a growing body of literature has revealed multiple pathways mediating bidirectional communication between the intestine and the CNS, collectively referred to as the gutbrain axis. In particular, microbes naturally colonizing the mammalian gastrointestinal (GI) tract, termed the gut microbiota, not only correlate with but play a causative role in regulating CNS function, development and behavior. Despite these findings, our understanding of the cellular and molecular mechanisms that mediate gut-brain communication remains in its infancy. However, members of the gut microbiota have been established as potent modulators of intestinal, systemic and CNS-resident immune cell function, suggesting that gut-brain interactions may involve the host immune system. Indeed, multiple CNS disorders with gut microbiota associations, including neuroinflammatory, neuropsychiatric and neurodegenerative disorders, also have significant inflammatory manifestations. In this review, I discuss recent advances exploring the role of microbiota-immune interactions as a critical regulator of the gutbrain axis in the context of CNS and related disorders. Gut microbes are potent regulators of host immune responses J o u r n a l P r e -p r o o f Journal Pre-proof
receptors (TLRs) and Nod-like receptors (NLRs) to produce the pro-inflammatory cytokine IL-1 (Thaiss et al., 2016) . Release of IL-1 activates ILC3s to produce granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-2, which maintains regulatory T cell (Treg) homeostasis and oral tolerance to dietary antigens (Mortha et al., 2014; Zhou et al., 2019) . The gut microbiota also plays an important role in shaping adaptive immune cell function (Belkaid and Harrison, 2017) . Most notably, gut microbes regulate the balance between pro-inflammatory T helper 17 cells (Th17) and antiinflammatory Tregs in the GI tract, which establishes immune homeostasis to prevent pathological intestinal and systemic inflammation. Furthermore, gut microbes are involved in T cell-dependent and independent B cell activation and subsequent release of intestinal and systemic immunoglobulins (Ig) that limit inflammatory responses towards gut microbes themselves. The specific cellular and molecular pathways by which gut microbes modulate innate and adaptive immune homeostasis have been extensively reviewed (Belkaid and Harrison, 2017; Britanova and Diefenbach, 2017; Thaiss et al., 2016) .
GF and ABX animals have been invaluable tools for functional studies to evaluate the immunological effects of various microbial species commonly found in a healthy gut microbiota. In mice, colonization of GF animals with segmented filamentous bacteria also colonized by endogenous viruses known as the gut virome (Neil and Cadwell, 2018) . In mice, mouse norovirus (MNV) is a viral pathogen that infects intestinal myeloid cells but can remain dormant following resolution of infection, thereby establishing persistence along the GI tract. Colonization of GF or ABX mice with MNV induces type 1 interferon responses that protect the host from enteric pathogen infection and chemical-induced intestinal injury (Kernbauer et al., 2014) , suggesting that similar to gut bacteria, intestinal viral infection can serve host protective functions. Consistent with this, a recent study demonstrates that SPF mice depleted of endogenous intestinal viruses with a cocktail of anti-viral compounds (ribavirin, lamivudine and acyclovir) have reduced levels of intraepithelial lymphocytes (IELs). These mice are more susceptibility to chemical-induced intestinal inflammation, which is rescued by IL-15 administration to restore IEL homeostasis (Liu et al., 2019a) . Altogether, these findings support the hypothesis that in addition to gut bacteria, the gut mycobiome and virome are emerging as critical immunomodulators with physiological consequences (Figure 1 ).
Gut microbes promote peripheral immune responses associated with CNS disorders

IL-17A in multiple sclerosis and autism
The immunomodulatory effects of the gut microbiota are becoming increasingly appreciated in tissues beyond the GI tract, as gut microbe-immune interactions play an important role in the etiology of neuroinflammatory and neuropsychiatric disorders. Early J o u r n a l P r e -p r o o f studies in microbiota-depleted animals have shown that CNS development, function, as well as mood and behavior (Lu et al., 2018; Vuong et al., 2017) are significantly impaired compared to microbiota-replete controls, suggesting that the gut microbiota plays a critical role in neurological function throughout life. One of first links supporting this hypothesis came from studies testing the role of the mouse indigenous gut bacteria, SFB, on susceptibility to experimental autoimmune encephalomyelitis (EAE), a rodent model for multiple sclerosis (MS). GF mice are highly resistant to EAE compared to SPF mice (Lee et al., 2011) . However, SFB colonization alone in GF mice is sufficient to induce extra-intestinal Th17 cells and EAE disease. Furthermore, loss of homeostatic control of the SFB-Th17 axis in intestinal-specific IL -17R-deficient animals results in exacerbated EAE severity (Kumar et al., 2016) . Conversely, Bacteroides fragilis and Prevotella histicola colonization suppresses disease in EAE by promoting Treg function (Mangalam et al., 2017; Ochoa-Reparaz et al., 2010) . In humans, intestinal Th17 cell responses positively correlate with MS disease and negatively correlate with the relative abundance of Prevotella in the human small intestine (Cosorich et al., 2017) , suggesting that Prevotella is an important modulator of neuroinflammation in both EAE and MS.
Transplantation of human MS fecal samples to GF mice induces a less potent antiinflammatory Treg response compared to healthy fecal samples and facilitates the development of spontaneous and induced EAE (Berer et al., 2017; Cekanaviciute et al., 2017) . Altogether, these findings illustrate that cytokine responses involved in the CNS inflammation can be modulated by immunomodulatory gut microbes (Table 1) .
Studies using the rodent model of autism, maternal immune activation (MIA), identify a similar gut microbe-immune axis whereby SFB colonization is sufficient to promote autism spectrum disorder (ASD)-like symptoms through Th17 cells (Choi et al., 2016; Kim et al., 2017; Lammert et al., 2018; Shin Yim et al., 2017) (Table 1) . MIA-induced systemic release of IL-17A in pregnant dams contributes to abnormal patch development in the dysgranular zone of the primary somatosensory cortex (S1DZ) in the offspring brain (Choi et al., 2016; Shin Yim et al., 2017) . Later studies identify intestinal Th17 cells as the source of IL-17A, which are significantly elevated when animals are colonized with SFB (Kim et al., 2017; Lammert et al., 2018) . Treatment of dams with anti-IL-17A neutralizing antibody limited cortical patch development and behavioral abnormalities (Choi et al., 2016; Lammert et al., 2018) . These findings are consistent with the clinical reports identifying significant microbiota associations in human ASD and suggest a causative role for gut microbes in regulating a subset of ASD symptoms (Kang et al., 2019; Sharon et al., 2019; Wang et al., 2019) (Table 1) .
Under homeostatic conditions, intestinal Th17 responses driven by gut microbes are non-inflammatory and host tissue-protective (Omenetti et al., 2019) . However, in the context of immune challenge or loss of immunological tolerance, gut microbes can drive inflammatory Th17 cell responses that can contribute to inflammatory disease (Omenetti et al., 2019; Xu et al., 2018) . Recent studies highlight differential functions of IL-17A and IL-17F, both produced by Th17 cells, in microbe-mediated intestinal inflammation (Tang et al., 2018) . While many studies on Th17 cells focus on the functions of IL-17A, investigating the mechanisms that balance protective versus pathogenic microbiota-J o u r n a l P r e -p r o o f dependent Th17 responses will be critical to understanding the role of microbiotaimmune crosstalk in neuroinflammatory disease.
Low-grade systemic inflammation in neuropsychiatric disorders
Elevated levels of circulating pro-inflammatory cytokines IL-1, IL-6 and TNF are associated with neuropsychiatric disorders in humans (Chu et al., 2019; Khandaker et al., 2018; Kohler et al., 2017; Treadway et al., 2019) . However, the cellular sources of these cytokines and the pathways by which they are induced are not well understood.
Furthermore, whether these responses are a cause or consequence of neuropsychiatric symptoms is not well understood. Low grade systemic inflammation is observed in rodent models of anxiety and depression (Hodes et al., 2014; Zhang et al., 2017) , and is associated with impaired intestinal barrier function (de Punder and Pruimboom, 2015) ( Table 1) . One consequence of a disrupted GI barrier is the translocation of gut microbes, leading to impaired intestinal immune homeostasis and systemic immune activation (de Punder and Pruimboom, 2015) . The inflammasome, a class of cytosolic innate immune receptors that recognizes intracellular microbe-and damage-associated molecular patterns (MAMPs, DAMPs), has emerged as a critical pathway involved in regulating microbiota-immune interactions (Man, 2018) . Activation of the inflammasome pathway results in caspase 1-or 11-mediated cleavage and release of the proinflammatory cytokines IL-1 and IL-18 (Yang et al., 2019) . Classically known to respond to intracellular bacterial pathogens such as Shigella, Salmonella and Legionella, recent studies suggest that inflammasomes play an important role in J o u r n a l P r e -p r o o f coordinating interactions between the healthy gut microbiota and host immune system (Levy et al., 2015; Man, 2018) . Loss of the NLRP3-and NLRP6-inflammasomes is associated with altered microbiota composition and increased susceptibility to colitis (Henao-Mejia et al., 2012; Wlodarska et al., 2014; Yao et al., 2017) , a condition often associated with systemic inflammation observed in neuropsychiatric disorders.
Interestingly, caspase-1-deficient mice, which lack inflammasome signaling and are protected from chemical-induced intestinal inflammation (Blazejewski et al., 2017) , have reduced anxiety-and depressive-like behaviors following chronic restraint stress (Wong et al., 2016) . However, whether these behavioral changes are a result of impaired microbiota-inflammasome interactions require further investigation.
Functional associations between gut microbiota composition and stress-induced depression are beginning to be elucidated. Animal models of physiological and psychological stress lead to altered gut microbiota composition (McGaughey et al., 2019; Werbner et al., 2019; Wong et al., 2016) and fecal transplantation regulates depressive-like symptoms through metabolic and inflammatory pathways (Kelly et al., 2016; Pearson-Leary et al., 2019; Zheng et al., 2016) , suggesting that the gut microbiota contributes to stress-induced depression (Table 1) Smith et al., 2013) , future studies should investigate whether these taxa are causally related to depression through immunomodulation.
Chronic intestinal inflammation and neurodegenerative disorders
IBD is a chronic inflammatory condition that affects the mammalian GI tract. The etiology of IBD is multifactorial with genetic and environmental components. Among the many diseases associated with the microbiota, the causal role of the microbiota in IBD has been the most extensively explored (Britton et al., 2019) . In IBD, gut microbes are potent drivers of pathologic intestinal inflammation, in part due to breakdown of physical and immune mechanisms that maintain separation between gut microbes and the host immune system (Ananthakrishnan et al., 2018) . Epidemiological data have linked IBD with various neuropsychiatric and neurodegenerative disorders (Villumsen et al., 2019) .
For example, patients with IBD are 22% more likely to develop Parkinson's disease (PD) than healthy controls. In fact, there is considerable overlap between genetic susceptibility loci in IBD and PD. These associations suggest that chronic inflammation in the intestine, which is significantly affected by the gut microbiota, modulate susceptibility to neurodegeneration. Despite these observations, the pathways by which chronic intestinal inflammation affects neuropathophysiology is not well understood.
Immune dysregulation in neurodegenerative diseases share common signatures with IBD including elevated T helper 1 (Th1), Th17 and reduced Treg responses, (Ananthakrishnan et al., 2018; Chitnis and Weiner, 2017) . In addition, IBD is associated with loss of intestinal barrier function, microbial translocation and systemic immune J o u r n a l P r e -p r o o f Journal Pre-proof activation (Sartor, 2008) . Consistent with this, PD patients exhibit increased intestinal permeability (Perez-Pardo et al., 2019) , disrupting homeostatic interactions between gut microbes and the host immune system (Table 1) . Multiple hypotheses have been proposed to explain the functional link between chronic intestinal inflammation and neurodegeneration: 1) imbalance of pro-versus anti-inflammatory gut microbes (Ho et al., 2018; Wu et al., 2017) , 2) systemic inflammation due to loss of intestinal barrier function and microbial translocation (Perez-Pardo et al., 2019) and 3) influence of microbial amyloids on host amyloidosis (Friedland and Chapman, 2017) . One intriguing hypothesis that has not been explored is the role of aging in mediating microbiota effects on neurodegeneration. Age-related deficits in immune function such as germinal center formation in gut-associated lymphoid tissues can be corrected by fecal microbiota transplantation from a young animal (Stebegg et al., 2019) . Additional studies are necessary to determine the functional role of age-related microbiota variation and immune dysfunction in PD and Alzheimer's disease (AD).
Alterations in gut microbial taxa with pro-inflammatory and anti-inflammatory properties have been observed in AD (Table 1 ). The gut microbiota of AD patients with brain amyloidosis are enriched for Escherichia coli and Shigella (Cattaneo et al., 2017) , which are potent pro-inflammatory drivers of chronic IBD (Palmela et al., 2018) and acute intestinal inflammation (Sansonetti, 2001) . The abundance of E. coli and Shigella correlates with expression of inflammatory genes Il1b, Nlrp3 and Cxcl2 in the peripheral blood. These findings are consistent with Helicobacter intestinal infection in humans (Kountouras et al., 2006) and enteric bacterial infection in Drosophila (Wu et al., 2017) J o u r n a l P r e -p r o o f positively associated with the pathogenesis and progression of AD. In the latter study, neuroinflammation and AD neuropathology triggered by oral infection with an enteric pathogen are dependent on immune hemocyte recruitment to the brain. The gut microbiota of AD patients diagnosed with dementia has reduced abundance of Clostridium, which correlates with elevated CSF levels of A42/A40 ratio, phosphorylated tau and phosphorylated tau/A42 ratio (Vogt et al., 2017) . However, the host immune consequences were not explored.
Despite growing interest in intestinal fungal and viral communities on chronic immune activation and IBD (Wheeler et al., 2017) , their role in CNS disorders is not well characterized. However, links between fungal infections and associated immune responses have been reported primarily in MS, but also in AD and amyotrophic lateral sclerosis (ALS) (Forbes et al., 2018) . One recent report demonstrates that Crohn's disease (CD) patients are more likely to be colonized with the common skin yeast, Malassezia restricta, in the intestinal mucosa (Limon et al., 2019) . Colonization of mice with M. restricta, but not the fungal microbe Candida albicans, increases susceptible to chemical-induced colitis, suggesting that the gut mycobiota affects host immunity in a species-specific manner. Additional studies are required to determine the role of fungalmediated intestinal inflammation on the development and pathogenesis of neurodegenerative disorders. Neurodevelopmental, neuropsychiatric and neurodegenerative disorders have all been associated with impaired microglia function. Although a number of genetic factors regulating microglia activity has been characterized, the influence of environmental factors such as the gut microbiota is beginning to be elucidated. Microglia in microbiotadepleted animals have altered inflammatory gene expression profiles and adopt an immature state (Erny et al., 2015) . More recent studies have shown that the role of the microbiota on microglia function is development-and sex-dependent (Thion et al., 2018) . Despite these findings, the precise mechanisms by which microbes from the gut can affect brain-resident microglial remain unclear. The microbe-derived fermentation product of dietary fiber, SCFAs, can restore microglia dysfunction in GF and ABX animals (Erny et al., 2015) , suggesting that microbial metabolites may be a general mechanism for gut-brain interactions. Consistent with this, dietary metabolites of tryptophan produced by the gut microbiota are involved in regulating microglial production of TGF and VEGF-B, which limit CNS inflammation during EAE and human MS (Rothhammer et al., 2018) . Taken together, these studies demonstrate that J o u r n a l P r e -p r o o f microbial signals originating from the intestine can have long-range effects in modulating microglia function.
Gut microbes have long-range effects on tissue-resident CNS immune function
Astrocytes
In addition to microglia, astrocytes are major cellular players among glia that participate in the maintenance of CNS health and disease (Valori et al., 2019) . Astrocytes provide support to endothelial cells that form the blood brain barrier and also play immune regulatory roles in CNS development and inflammation through antigen presentation, and cytokine and chemokine production. Astrocyte function can be modulated by dietary metabolites of tryptophan produced by the gut microbiota (Rothhammer et al., 2016) .
During EAE, type 1 interferons activate an anti-inflammatory pathway in astrocytes through the cytosolic transcription factor, aryl hydrocarbon receptor (AHR). AHR activation is dependent on indoles produced by ampicillin-sensitive gut microbes as byproducts of dietary tryptophan metabolism. Bacterial tryptophanases, which catalyze tryptophan to indoles and related compounds, are highly expressed by specific members of gut microbes including Lactobacilli (Zelante et al., 2013) , Escherichia coli (Li and Young, 2013) and Bacteroides (Devlin et al., 2016) , suggesting that metabolic activities of these microbes are involved in regulating AHR-expressing astrocytes.
Astrocytes release the IL-1 family cytokine IL-33 to activate microglial synapse engulfment (Vainchtein et al., 2018) , highlighting a cytokine-mediated pathway by which astrocytes regulate neural circuitry remodeling, although a role of the gut microbiota in J o u r n a l P r e -p r o o f this pathway has not been explored. Altogether, these findings illustrate that gut microbial metabolism regulates immune-related functions in astrocytes.
CNS-resident innate and adaptive immune cells
Previous work has linked AHR signaling regulated by microbial metabolites of tryptophan to IL-22 production at mucosal tissues (Zelante et al., 2013) . More recent studies illustrate that cell-intrinsic AHR activation in ILCs (Li et al., 2018) , B cells (Villa et al., 2017) and intestinal epithelial cells (Metidji et al., 2018) modulate specific functions in anti-helminth immunity and anti-tumor responses. Given the effect of AHR ligands on astrocytes, this raises the possibility that the function of other AHR-expressing innate (ILCs) and adaptive cells (T cells) resident in the CNS can be similarly modulated. CNSresident plasma cells and IgA of intestinal origin are also implicated in the pathogenesis of EAE (Rojas et al., 2019) . Tissue-resident plasma cells and plasmablasts produce the immunoregulatory cytokine IL-10 to suppress neuroinflammation. Collectively, these findings suggest that gut microbes can affect CNS-resident innate and adaptive immune cell functions with neuropathological consequences.
Therapeutic implications targeting the microbiota-immune axis
The gut microbiota plays a critical role in modulating the development and pathogenesis of neuroinflammation in EAE, which is supported by clinical associations between gut microbiota composition and human MS (Berer et al., 2017; Cekanaviciute et al., 2017;  J o u r n a l P r e -p r o o f Journal Pre-proof Chen et al., 2016; Jangi et al., 2016) . Existing immune-based therapeutics, such IFN-, have been effective at limiting neuroinflammation in MS. Despite a large body of evidence supporting a pathogenic role for IL-17A in MS, antibody-based therapeutics targeting this pathway have produced mixed results (Steinman, 2010) , potentially due to neutralization of tissue-protective functions of IL-17A (McGeachy et al., 2019) .
Therefore, approaches to target the microbiota through probiotic administration, dietary intervention and fecal microbiota transplantation (FMT) are being explored as alternative strategies (Figure 2 ).
Clinical trials have tested probiotic administration alone or in combination with existing
MS medications with promising outcomes (Tankou et al., 2018a; Tankou et al., 2018b) .
VSL3, a probiotic cocktail of 8 bacteria strains, administered to MS patients and healthy controls twice daily for two months, transiently elevates the relative abundance of VSL3derived strains in the gut microbiota and decreases frequencies of circulating inflammatory monocytes and expression of activation markers CD80 and HLA-DR on blood monocytes and dendritic cells, respectively (Tankou et al., 2018a; Tankou et al., 2018b) . A separate clinical trial with only MS patients administered a similar probiotic cocktail of Lactobacillus spp. and Bifidobacterium once daily for 3 months, which results in improvements in mental health and reduction in circulating inflammatory markers (Kouchaki et al., 2017) . Clinical studies evaluating the use of FMT in large cohorts of individuals with CNS disorders are limited. One case report in a secondary progressive MS patient demonstrates beneficial outcomes following FMT (Makkawi et al., 2018) . In ASD, an open-label FMT trial reveals long-term GI and autism-related health benefits in J o u r n a l P r e -p r o o f 18 pediatric patients (Kang et al., 2019) . Based on these preliminary findings, additional randomized, double-blinded trials employing targeted probiotics or FMTs to treat various neurophysiological and behavioral disorders are necessary and currently in progress (www.clinicaltrials.gov).
Mood disorders including major depressive disorder, mild chronic depression, and bipolar disorder affect 9.7% of adults in the United States each year with a lifetime prevalence of 21.4% (Kessler et al., 2009; Kessler et al., 2005) . Similarly, anxiety disorders, which include generalized anxiety, panic disorder, social anxiety and obsessive-compulsive disorders, affect 19% of the US adult population each year with a lifetime prevalence of 31% (Kessler et al., 2009; Kessler et al., 2005) . These statistics coincide with a 65% increase in use of anti-depressant medications from 1999-2004 (Pratt et al., 2017) . Use of anti-depressants and anti-psychotics modulates the inflammatory environment (Hou et al., 2019; Szalach et al., 2019) and are linked to changes in the human gut microbiota (Jackson et al., 2018; Lukic et al., 2019; Maier et al., 2018) . These data suggest that modulation of systemic immune activation by these medications may partially occur through changes to the gut microbiota. A growing body of animal and clinical findings illustrating causal relationships between the gut microbiota and symptoms of mood disorders suggests that modulating the composition and function of the gut microbiota may be an effective therapeutic approach and alternative to anti-depressants and anti-psychotics. Clinical studies to test microbialbased therapeutics, however, have been met with mixed results. Meta-analyses of clinical probiotic use in depression and schizophrenia only found a modest beneficial J o u r n a l P r e -p r o o f effect in a subset of studies (Ng et al., 2018; Ng et al., 2019) , while several newer studies demonstrate improvement in depression symptoms (Chahwan et al., 2019; Wallace et al., 2019) . Lack of reproducible efficacy using commercially available probiotics may be due to poor mucosal colonization and persistence of ingested strai ns (Suez et al., 2018; Zmora et al., 2018) . These findings warrant additional clinical investigation to measure host determinants of probiotic colonization, such as endogenous gut microbiota composition, host metabolism and immune status, between probiotic-responsive and non-responsive patient cohorts. More importantly, rational design of specific bacterial strains with immunological potential, especially those that are depleted in diseased the gut microbiota, should be considered in future trials.
Adherence to a Mediterranean diet, which provides a rich source of dietary fiber for gut microbial fermentation and generation of anti-inflammatory SCFAs, is negatively associated with depressive symptoms (Gialluisi et al., 2019) . However, meta-analysis of clinical prebiotic use indicated a lack of improvement in depression and anxiety compared to probiotic use (Liu et al., 2019b) . Since dietary tryptophan can modulate susceptibility to MS (Nourbakhsh et al., 2018) potentially through the microbiota (Rothhammer et al., 2016; Sonner et al., 2019) , a prebiotic therapy that modulates microbial tryptophan metabolism and downstream AHR-immune responses to treat neuroinflammation is worth exploration. More importantly, future human trials should evaluate the specific prebiotic components tailored to enrich gut bacterial species with anti-inflammatory and neuroprotective potential in a disease-specific manner.
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Concluding remarks
The GI tract is colonized with trillions of indigenous microorganisms that shape local and extra-intestinal host immune function. Dysregulated immune responses are increasingly appreciated as drivers of not only neuroinflammatory, but also neuropsychiatric and neurodegenerative diseases. New findings in animal and human studies implicate the gut microbiota as a significant contributor of immune dysregulation in various CNS disorders. Gut microbes directly modulate intestinal and systemic immune homeostasis to affect neuroinflammation and may contribute to low grade systemic inflammation in neuropsychiatric disorders. Pathological immune activation to gut microbes, a feature of chronic intestinal inflammation, is also a significant risk factor for neurodegeneration. Furthermore, the gut microbiota regulates the function of CNSresident immune cells with potential consequences for neurodevelopmental and neuroinflammatory conditions. Therefore, targeting the microbiota-immune axis is a promising therapeutic approach for treating CNS and related disorders. Targeting the microbiota-immune axis is a promising therapeutic strategy to treat CNS disorders. This can be achieved by 1) administration of probiotic strains that promote immunosuppressive responses and limit pathological inflammation 2) ingestion of diets or prebiotic formulations that supply nutrients to modulate gut microbial metabolism and J o u r n a l P r e -p r o o f release of anti-inflammatory by-products, 3) replacing a "diseased" gut microbiota with that of a healthy individual to restore beneficial microbial populations and/or eliminate pathological strains. Use of immunotherapeutic agents that directly target the host immune system in combination with microbial-based therapeutics may be more effective than immunotherapy alone to treat specific nervous system disease states. Alzheimer's disease -Amyloid-positive AD has elevated Escherichia coli and Shigella, which correlates with systemic expression of Il1b, Nlrp3 and Cxcl2; amyloidpositive AD has reduced abundance of Eubacterium rectale, which is negatively associated with Il1b, Nlrp3, Cxcl2 and positively associated with Il10 -E. coli/Shigella and E. rectale are positively and negatively associated with brain amyloidosis, respectively (Cattaneo et al., 2017) -Immune consequences not reported -Reduced and increased abundance of Firmicutes (Vogt et al., 2017) and Bacteroidetes, respectively, in AD, correlate with CSF biomarkers -Helicobacter pylori intestinal infection promotes proinflammatory innate and adaptive immune responses -Positively associated with AD (Kountouras et al., 2006) -Intestinal infection with enterobacteria in Drosophila promotes hemocyte recruitment and immune activation in the brain -Enhances AD neurodegeneration (Wu et al., 2017) Parkinson's disease (PD) -Anti-TNF is used to suppress intestinal and systemic inflammation in IBD -Anti-TNF in IBD patients is associated with 78% reduction in incidence of PD (Peter et al., 2018) -IBD is associated with altered immune response to gut microbiota -IBD patients have 22% increased risk of PD, with UC patients slightly higher risk compared to CD (Villumsen et al., 2019) -PD has reduced expression of tight junction proteins, increased expression of TLR4, CD3, other inflammatory biomarkers in colonic mucosa -Positively associated with PD 
